ストックスクリーナーアプリを入手
12.17
0.81%
-0.10
前日終値:
$12.27
開ける：
$12.27
24時間の取引高:
1.26M
Relative Volume:
6.11
時価総額：
$208.18M
収益：
$10.73M
当期純損益:
$-455.74M
株価収益率:
-3.2171
EPS:
-3.7829
ネットキャッシュフロー:
$-502.70M
1週間 パフォーマンス:
+3.66%
1か月 パフォーマンス:
-2.33%
6か月 パフォーマンス:
-83.31%
1年 パフォーマンス:
-73.68%
1日の値動き範囲:
$12.06
$12.35
1週間の範囲:
$11.88
$12.48
52週間の値動き範囲:
$11.13
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
名前
Atrium Therapeutics Inc
セクター
電話
858-401-7900
住所
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
12.17 | 209.89M | 10.73M | -455.74M | -502.70M | -3.7829 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | 開始されました | Wells Fargo | Overweight |
| 2025-09-17 | 開始されました | Roth Capital | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Bernstein | Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Atrium Therapeutics Inc (RNA) 最新ニュース
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market - DirectorsTalk Interviews
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - moomoo.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Atrium Therapeutics (RNA) Climbs 1.99% to $11.77, Approaching Key Resistance at $12.36Volume Oscillator - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A 120% Upside Potential Awaits Investors - DirectorsTalk Interviews
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - TradingView
Atrium Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockEarnings Outlook Update - dars.gov.et
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics’ new hire receives options and 3,500 stock units - Stock Titan
Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Commercial Spend Weighs on ResultsQuarterly Profit Report - dars.gov.et
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Provides a Modest SurpriseLow Estimate Range - dars.gov.et
Wells Fargo Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atrium’s ATR-1072 gains IND clearance for PRKAG2 syndrome - BioWorld News
Atrium Therapeutics Receives FDA Clearance for ATR 1072, Launches First Clinical Trial Targeting PRKAG2 Syndrome - Minichart
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug - dicardiology.com
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
Atrium Therapeutics Secures FDA Clearance for ATR 1072 Trial - grafa.com
Atrium gets FDA clearance for PRKAG2 syndrome trial - Investing.com UK
Atrium gets FDA clearance for PRKAG2 syndrome trial By Investing.com - Investing.com Nigeria
FDA clears Atrium Therapeutics' IND for ATR 107... - Pluang
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - PR Newswire
Atrium Therapeutics (RNA) Slips 3.5% as Biotech Headwinds IntensifySuperTrend - dars.gov.et
Enterprise value to revenue forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to earnings forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Enterprise value to EBIT forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to sales forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Atrium Therapeutics Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Atrium Therapeutics (RNA) Slips 3% as Shares Test Key Support at $12.31Delta Hedging - dars.gov.et
RNA News | ATRIUM THERAPEUTICS INC (NASDAQ:RNA) - ChartMill
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat on Narrower Loss, No Revenue Reported - dars.gov.et
Atrium Therapeutics, Inc.(NasdaqGS:RNA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Company Poised for Nearly 90% Upside - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Growth Benchmark - marketscreener.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Clinical ProgressFiscal Year Earnings - dars.gov.et
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell Microcap Index - marketscreener.com
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Index - marketscreener.com
RNA Forecast — Price Target — Prediction for 2027 - TradingView
Atrium Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNA) - TradingView
RNA Technical Analysis & Stock Price Forecast - Intellectia AI
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline Progress ContinuesManagement Tone Analysis - po-news-eg.net
Arbiter Partners Capital Management LLC's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Cantor Fitzgerald Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Stage; Stock Inches HigherOperating Margin Analysis - Město Břeclav
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pipeline Progress - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status; Stock Drops on Cash Burn ConcernsEPS Miss Report - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amidst Clinical Progress and Cost DisciplineMid-Term Outlook - dars.gov.et
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Atrium Therapeutics Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
5.12%
0.22%
大文字化:
|
ボリューム (24 時間):